Evening Primrose

Evening primrose oil (EPO) contains gamma-linolenic acid (GLA), which inhibits platelet aggregation through inhibition of thromboxane A2 synthesis and modification of platelet membrane fatty acid composition. Combined with warfarin, the antiplatelet effect of EPO potentiates anticoagulation and significantly raises bleeding risk.

Patients on warfarin should avoid concurrent use of EPO without medical supervision. Monitor INR more frequently if EPO is co-administered. Discontinue EPO at least 2 weeks before elective surgery. Educate patients about bleeding warning signs.

Evening primrose oil has been reported to interact with phenothiazine antipsychotics by lowering the seizure threshold. The proposed mechanism involves GLA metabolites altering neuronal membrane fluidity and GABA receptor function, increasing neuronal excitability in patients who are already susceptible to seizures due to phenothiazine effects.

Patients with schizophrenia or psychosis who are treated with phenothiazines should not take EPO. This combination is potentially contraindicated. Clinicians should advise against EPO use in patients on phenothiazine therapy.

There are historical concerns that GLA-containing oils like EPO may lower the seizure threshold and reduce the effectiveness of anticonvulsants. However, more recent evidence (Puri 2007) suggests that linolenic and linoleic acids from EPO may actually protect against seizures in animal models. The interaction remains controversial and warrants caution.

Patients with epilepsy or those on anticonvulsant therapy should discuss EPO use with their neurologist. While recent research is more reassuring, formulary guidance still lists seizure history as a precaution. Monitor seizure frequency if EPO is introduced.

EPOs GLA content reduces platelet aggregation by shifting arachidonic acid metabolism toward less pro-aggregatory prostaglandins. When combined with aspirin or NSAIDs, which also inhibit cyclooxygenase and platelet function, the antiplatelet effect is additive, increasing the risk of prolonged bleeding time.

Advise patients on aspirin therapy or regular NSAID use to exercise caution with EPO, particularly at high doses. Monitor for signs of excessive bleeding, bruising, or GI bleeding. Discontinue EPO 2 weeks prior to any surgical procedure.

EPO has been identified as a potential modulator of CYP3A4 activity. As lopinavir/ritonavir are both CYP3A4 substrates and inhibitors with a narrow therapeutic window, any alteration of CYP3A4 function could affect plasma levels of these critical antiretroviral agents, potentially leading to treatment failure or toxicity.

Patients on HIV antiretroviral therapy with lopinavir/ritonavir or other CYP3A4-dependent antiretrovirals should consult their HIV specialist before using EPO. Therapeutic drug monitoring may be warranted if EPO use cannot be discontinued.